Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Yamasa describes cognition-enhancing agents

April 24, 1997

Arzneimittelwerk describes new anticonvulsants

April 24, 1997

Grape seed proanthocyanidins compared to other antioxidants in vitro and in vivo

April 24, 1997

Canadian clearance for Naropin

April 23, 1997

Positive clinical results for mitoxantrone in multiple sclerosis

April 23, 1997

Piracetam as an adjuvant to language therapy for aphasia

April 23, 1997

Novel 5-HT uptake inhibitors from Bristol-Myers Squibb

April 23, 1997

AutoImmune freezes development of Myloral

April 22, 1997

BASF selects dual D4/5-HT2 antagonist for clinical development

April 22, 1997

MS&D designs potent and selective dopamine D4 antagonist

April 21, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.